The stock price of Cidara Therapeutics Inc (NASDAQ: CDTX) has dropped by -6.44 compared to previous close of 25.93. Despite this, the company has seen a gain of 0.87% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-25 that Cidara Therapeutics’ CD388 is a long-acting influenza antiviral aimed at providing universal protection with a single yearly dose for each flu season. In contrast to vaccines, CD388’s efficacy is not dependent on circulating strains or on an intact patient immune system. CD388 is ideal for pandemic preparedness and for high-risk patients. Readout of a randomized ph2b trial of CD388 is expected by the end of June, with the potential to serve as one of the two needed trials for approval.
Is It Worth Investing in Cidara Therapeutics Inc (NASDAQ: CDTX) Right Now?
The 36-month beta value for CDTX is also noteworthy at 0.80. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CDTX is 7.67M, and at present, short sellers hold a 6.18% of that float. The average trading volume of CDTX on June 13, 2025 was 172.56K shares.
CDTX’s Market Performance
CDTX stock saw an increase of 0.87% in the past week, with a monthly gain of 25.31% and a quarterly increase of 8.50%. The volatility ratio for the week is 4.13%, and the volatility levels for the last 30 days are 5.79% for Cidara Therapeutics Inc (CDTX). The simple moving average for the past 20 days is -0.49% for CDTX’s stock, with a 29.16% simple moving average for the past 200 days.
Analysts’ Opinion of CDTX
Many brokerage firms have already submitted their reports for CDTX stocks, with Citizens JMP repeating the rating for CDTX by listing it as a “Mkt Outperform.” The predicted price for CDTX in the upcoming period, according to Citizens JMP is $46 based on the research report published on March 12, 2025 of the current year 2025.
RBC Capital Mkts gave a rating of “Outperform” to CDTX, setting the target price at $34 in the report published on December 13th of the previous year.
CDTX Trading at 12.94% from the 50-Day Moving Average
After a stumble in the market that brought CDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.64% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDTX starting from Mineo Chrysa, who purchase 2,270 shares at the price of $21.71 back on Jun 02 ’25. After this action, Mineo Chrysa now owns 2,270 shares of Cidara Therapeutics Inc, valued at $49,281 using the latest closing price.
Mineo Chrysa, the Director of Cidara Therapeutics Inc, purchase 1,050 shares at $23.44 during a trade that took place back on Jun 03 ’25, which means that Mineo Chrysa is holding 3,320 shares at $24,614 based on the most recent closing price.
Stock Fundamentals for CDTX
Current profitability levels for the company are sitting at:
- -357.44 for the present operating margin
- 0.81 for the gross margin
The net margin for Cidara Therapeutics Inc stands at -598.45. The total capital return value is set at -0.76. Equity return is now at value -299.58, with -151.85 for asset returns.
Based on Cidara Therapeutics Inc (CDTX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -71.77.
Currently, EBITDA for the company is -176.1 million with net debt to EBITDA at 1.54. When we switch over and look at the enterprise to sales, we see a ratio of 493.94. The receivables turnover for the company is 0.18for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.87.
Conclusion
In summary, Cidara Therapeutics Inc (CDTX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
